Form 4 for AMGN Amgen

Accepted 2023-05-09 00:00:00 ET · period of report 2023-05-05 · accession 0001127602-23-015051 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
	2023-05-09	2023-05-05	AMGN	REESE DAVID M	EVP, Research, Development	F - Tax	$231.89	-594	54.1K	-1%	-$137.7K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2023-05-05	F	D	594	$231.89	54,114	D	—	—	(F1) These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,180 RSUs which will vest on 5/5/2024; 2,685 RSUs which will vest in installments of 1,322 on 4/30/2024 and 1,363 on 4/30/2025; 3,897 RSUs which will vest in two installments of 1,286 on 5/2/2024 and 5/2/2025, and one installment of 1,325 on 5/2/2026; and 3,814 RSUs which will vest in installments of 1,258 on 5/2/2025, 1,259 on 5/2/2026, and 1,297 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. (F2) These shares include 418 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.